This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Amryt Pharma Croissance future
Future contrôle des critères 5/6
Informations clés
53.9%
Taux de croissance des bénéfices
50.8%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 19.6% |
| Taux de croissance des recettes | 26.3% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 12 Apr 2023 |
Mises à jour récentes de la croissance future
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 595 | 153 | N/A | N/A | 1 |
| 12/31/2024 | 428 | 141 | N/A | N/A | 2 |
| 12/31/2023 | 325 | -3 | 59 | N/A | 4 |
| 12/31/2022 | 266 | -64 | 34 | N/A | 4 |
| 9/30/2022 | 244 | -1 | 107 | 108 | N/A |
| 6/30/2022 | 239 | 3 | -32 | -30 | N/A |
| 3/31/2022 | 233 | 3 | 4 | 5 | N/A |
| 12/31/2021 | 223 | 1 | 14 | 16 | N/A |
| 9/30/2021 | 210 | -88 | -89 | -86 | N/A |
| 6/30/2021 | 203 | -81 | 46 | 50 | N/A |
| 3/31/2021 | 186 | -92 | 21 | 23 | N/A |
| 12/31/2020 | 183 | -105 | 24 | 27 | N/A |
| 9/30/2020 | 180 | -87 | 5 | 6 | N/A |
| 6/30/2020 | 140 | -92 | -18 | -17 | N/A |
| 3/31/2020 | 98 | -87 | -26 | -26 | N/A |
| 12/31/2019 | 58 | -63 | -38 | -37 | N/A |
| 12/31/2018 | 17 | -30 | -16 | -15 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 3N9A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Bénéfices vs marché: 3N9A is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: 3N9A is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: 3N9A's revenue (26.3% per year) is forecast to grow faster than the German market (3.2% per year).
Croissance élevée des revenus: 3N9A's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if 3N9A's Return on Equity is forecast to be high in 3 years time